Roche CEO Thomas Schinecker told the “Financial Times” that the company’s first anti-obesity drugs would come onto the market “much faster than expected” – possibly by 2028. This booming market is currently dominated by the American company Eli Lilly and the Danish company Novo Nordisk.
In mid-July, Roche once again published positive study data on a potential weight loss drug. This involved the candidate CT-996, which is taken once a day to treat type 2 diabetes and obesity. The drug comes from the portfolio of the American company Carmot, which Roche acquired in December for around $3 billion.
Like several anti-obesity drugs in development, CT-996 belongs to the new class of lipid-lowering drugs, the GLP-1 drugs. It achieved significant results in two sub-studies of an ongoing multi-part Phase I clinical trial. Only shortly before this, Roche had published data on its other obesity candidate CT-388, which had been positively received by analysts and investors.
Schinecker told the Financial Times that Roche could have “around seven” drugs from the Carmot acquisition, some of which are in even earlier stages of development. Roche shares have also recently benefited from the trial data.
The multi-billion dollar market for so-called GLP-1 drugs is becoming increasingly competitive. Many pharmaceutical companies, including industry giants Pfizer and Boehringer Ingelheim, are working on competing products to those of Eli Lilly and Novo Nordisk.
Adapted from German by DeepL/ac
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles.
If you want to know more about how we work, have a look here, if you want to learn more about how we use technology, click here, and if you have feedback on this news story please write to english@swissinfo.ch.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
Popular Stories
More
Banking & Fintech
UBS releases ‘hundreds’ of staff in fresh wave of job cuts
As a Swiss Abroad, how do you feel about the emergence of more conservative family policies in some US states?
In recent years several US states have adopted more conservative policies on family issues, abortion and education. As a Swiss citizen living there, how do you view this development?
‘Confederation is a subsidy machine’: Swiss finance minister
This content was published on
The Swiss government is a machine for distributing subsidies to various actors in the country, says finance minister Karin Keller-Sutter.
Lack of funds ends third bid to salvage Säntis ship from Swiss lake
This content was published on
A third attempt to salvage the steamship Säntis, lying at the bottom of Lake Constance in Switzerland since 1933, has failed before it has even begun.
Nestlé Waters on trial in France over illegal waste dumps
This content was published on
Bottled water producer Nestlé Waters to stand trial, accused of illegally dumping waste and maintaining unauthorised dumps.
Swiss army chiefs defend botched procurement projects
This content was published on
Swiss defense Minister and military heads defend against parliamentary and media criticisms of problematic procurement projects.
Swiss cheese exports recorded second-best year in 2024
This content was published on
A total 79,268 tons of Swiss cheese worth CHF748.5 million was exported abroad in 2024 - a 7.9% increase in annual sales from the previous year.
This content was published on
Insects benefit from storm devastation, says a 20-year study by the Swiss Federal Institute for Forest, Snow and Landscape Research.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.